---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-065935"
form_type: "8-K"
ticker: null
cik: "0001169245"
company_name: "PhaseBio Pharmaceuticals Inc"
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T22:49:28.035246+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PhaseBio settles SFJ dispute in Ch.11; $2.5M admin claim, $27.8M unsecured claims

## Summary
- Settlement stipulates a $2.5M allowed administrative claim for SFJ, down from the $15.4M sought.
- SFJ receives $27.8M in aggregate general unsecured claims under the settlement.
- Plan requires sale of Bentracimab royalties within six months of BLA approval; if sale <$2.5M, royalty transfers to SFJ.
- SFJ will withdraw its objection and support the amended Chapter 11 Plan after Bankruptcy Court approval.
- November 2023 monthly report shows cash $2.55M, cumulative professional fees $14.2M, zero employees.

## SEC filing metadata
- accession: 0001193125-24-065935
- form_type: 8-K
- cik: 0001169245
- company_name: PhaseBio Pharmaceuticals Inc
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/0001193125-24-065935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/d759787d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-065935
- JSON: https://secwatch.observer/filing/0001193125-24-065935.json
- Plain text: https://secwatch.observer/filing/0001193125-24-065935.txt

## Key facts
- Material Agreements
  PhaseBio Pharmaceuticals Inc entered into Plan Support and Settlement Agreement with SFJ Pharma X, Inc. (effective 2024-03-06).
  - Action: entry
  - Agreement: settlement
  - Counterparty: SFJ Pharma X, Inc.
  - Effective: 2024-03-06
  source text: On March 6, 2024, the Company and SFJ executed and entered into a Plan Support and Settlement Agreement (the “Settlement Agreement”) to resolve the Motion to Allow, the Objection, and related matters.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1169245/000119312524065935/0001193125-24-065935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.